ArticleCancer innovation2024

Inetetamab combined with sirolimus and chemotherapy for the treatment of HER2-positive metastatic breast cancer patients with abnormal activation of the PI3K/Akt/mTOR pathway after trastuzumab treatment.

Qiao Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.